While glucocorticoids are used as first-line therapy for Duchenne muscular dystrophy (DMD), these agents are associated with several adverse events, including accelerated bone loss and muscle atrophy. As a result, prolonged glucocorticoid treatment is one of the primary contributors to the high fracture rate in patients with DMD.
Radiopharm Theranostics Ltd. has been granted human research ethics committee (HREC) approval to commence a first-in-human phase I study in Australia for RAD-204, the company’s radiotherapeutic for patients with PD-L1-positive non-small-cell lung cancer (NSCLC).
The structures of the majority of PD-1/PD-L1 inhibitors currently in use are derived from the arylmethylamine/biphenyl scaffold. Researchers from Southern Medical University reported on the discovery and preclinical evaluation of a novel series of non-arylmethylamine-based PD-1/PD-L1 inhibitors for use in cancer immunotherapy.
For most psychiatric illnesses, the precipitating event is mysterious. Many conditions are thought to result from a mix of genetic risk and environmental factors, but the specific trigger remains unknown. In post-traumatic stress disorder (PTSD), the environmental trigger is usually clear. In many cases, it is all the affected individuals can think about. “Intrusive reliving” of the triggering situation is one of the core features of PTSD.
Integral Molecular Inc. has been awarded funding totaling $896,000 from the National Institutes of Health (NIH), which will support its discovery of antibodies against difficult and conserved protein targets.
Guangzhou Maxinovel Pharmaceuticals Co. Ltd. has described thienopyrimidine compounds acting as ALK, fibroblast growth factor receptor (FGFR) and high affinity nerve growth factor (TRK) inhibitors reported to be useful for the treatment of cancer, infections and psoriasis and inflammation.
Nammi Therapeutics Inc. has divulged prodrugs of Toll-like receptor (TLR) agonists and its self-assembled lipid nanoparticles reported to be useful for the treatment of cancer and immunological disorders.
Scinnohub Pharmaceutical Co. Ltd. has identified S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Shanghai Ringene Biopharma Co. Ltd. has synthesized CDK7/cyclin H inhibitors reported to be useful for the treatment of cancer, hemolytic anemia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, sepsis, idiopathic thrombocytopenic purpura and ulcerative colitis, among others.
JS Innomed Holdings Ltd. has disclosed heterocyclic compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, LEOPARD syndrome and Noonan syndrome.